UPDATE: Goldman Sachs Reiterates Sell Rating, $62 PT on Humana

In a report published Wednesday, Goldman Sachs Group reiterated its Sell rating and $62.00 price target on Humana HUM. Goldman Sachs noted, “The focus of the investor day was the transition to provider-integrated care (owned and risk-contracted) that offers lower cost / higher quality outcomes versus traditional fee-for-service. With Medicare Advantage (MA) driving the majority of revenue and earnings, we think integrated care is the right model to better position Humana for tighter MA reimbursement as health reform rolls through and also the right model to strengthen Humana's role in easing the national Medicare cost crisis in the years ahead.” Humana closed on Tuesday at $68.29.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorReiterationAnalyst RatingsGoldman Sachs Group
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!